The incretin franchise trades price for volume as the US net-pricing regime resets through most-favoured-nation agreements, Medicare negotiation and Section 232 tariff conditionality

base_rate

• Medicare negotiation is not enjoined
• MFN agreements are renewed rather than allowed to lapse
• Oral incretin manufacturing scales without a supply interruption

• Indicator

  CMS publishes the cycle 4 selected-drug list on or before 2027-02-28, and it includes at least one Part B drug

  Source

  S-06-04

  Threshold

  list published by 2027-02-28

  Direction

  occurs

  Would Be Visible By

  2027-02

  Resolves

  Confirms base; slippage or contraction moves mass to regulatory

• Indicator

  Lilly full-year 2027 revenue guidance is above its 2026 realised revenue while Novo guides flat or lower

  Source

  S-06-10

  Threshold

  divergent guidance in the same quarter

  Direction

  occurs

  Would Be Visible By

  2027-02

  Resolves

  Confirms the uneven-incidence element of base

• Indicator

  Combined quarterly oral incretin revenue (oral Wegovy plus Foundayo) exceeds USD 1.2bn in any quarter of 2027

  Source

  S-06-11

  Threshold

  USD 1.2bn

  Direction

  above

  Would Be Visible By

  2027-11

  Resolves

  Confirms volume absorbing price

• Text

  Treated-patient growth exceeds net-price decline in percentage terms each year through 2029

  Confidence

  medium

  Load Bearing

  true

  Basis

  T-06-01 evidence: Lilly Q2 2026 revenue +48% to nearly USD 23bn while MFN cut list-to-net

  If Wrong

  Base and downside swap probability mass; the downside indicator of two consecutive quarters of declining category revenue would already have fired

• Text

  CMS continues annual cycles without programme redesign

  Confidence

  high

  Load Bearing

  false

  Basis

  S-06-04, three cycles completed on schedule

  If Wrong

  Mass moves to the regulatory branch

• 06
• 07
• 12

Distinguished from downside by the sign of category revenue, not by the size of price cuts. Base tolerates large price cuts as long as aggregate category revenue in USD keeps rising.

Two consecutive quarters of declining total incretin category revenue in USD across Lilly and Novo combined.

Model US branded pharmaceutical revenue on net price with an explicit government-set floor and ceiling rather than on list price. Payers and employers should budget for higher treated prevalence at lower unit cost, which is a volume-driven budget increase even as unit prices fall.

analogue

• Oral products beat rather than miss consensus for two consecutive quarters
• Oral manufacturing scales without an impurity or supply event
• At least one large non-US market registers an oral at a price near the TrumpRx level

• Indicator

  Combined quarterly oral incretin revenue exceeds USD 2.0bn in any quarter before 2028-06-30

  Source

  S-06-11

  Threshold

  USD 2.0bn

  Direction

  above

  Would Be Visible By

  2028-02

  Resolves

  Confirms upside; below USD 1.2bn keeps this in base

• Indicator

  A preclinical-stage biotech completes a US IPO raising USD 200m or more

  Source

  S-06-06

  Threshold

  USD 200m gross proceeds, preclinical lead asset

  Direction

  occurs

  Would Be Visible By

  2027-12

  Resolves

  Confirms the capital-formation leg of upside

• Text

  A small-molecule oral can be manufactured at a cost that supports a USD 150 monthly price at scale

  Confidence

  low

  Load Bearing

  true

  Basis

  T-06-14; the MFN framework prices orals from USD 150/month but no manufacturer has disclosed oral cost of goods

  If Wrong

  Upside collapses into base; nothing moves to downside

• Text

  Demand at USD 150 is limited by price rather than by prescriber willingness

  Confidence

  low

  Load Bearing

  false

  Basis

  Both 2026 oral launches missed Q2 consensus

  If Wrong

  Volume growth is slower and the branch stays in base

• 06
• 09
• 12
• 19

Requires disclosed oral revenue above the threshold, not prescription counts. Prescription growth alone leaves the outcome in base.

A third consecutive quarter in which both oral products miss consensus.

Contract manufacturers and tablet-formulation suppliers should treat this as the highest-value capacity question of the decade and seek take-or-pay terms rather than building on forecast.

base_rate

• Oral products continue to miss consensus
• No offsetting reimbursement expansion for weight management
• Policy rates do not fall materially

• Indicator

  Two consecutive quarters of declining total incretin category revenue in USD across Lilly and Novo

  Source

  S-06-10

  Threshold

  two consecutive quarters

  Direction

  occurs

  Would Be Visible By

  2027-08

  Resolves

  Confirms downside

• Indicator

  Fewer than three biotech IPOs priced on US exchanges in any calendar quarter

  Source

  S-06-13

  Threshold

  fewer than 3 in a quarter

  Direction

  below

  Would Be Visible By

  2027-07

  Resolves

  Confirms the capital-formation leg

• Text

  Oral incretin consensus misses reflect demand conversion rather than launch-phase supply allocation

  Confidence

  medium

  Load Bearing

  true

  Basis

  T-06-14: oral Wegovy USD 494m against DKK 3.6bn expected; Foundayo USD 98m against USD 104m

  If Wrong

  The downside indicator fires without the downside occurring, a false positive that must be published and scored

• Text

  Rate levels stay high enough to keep the long-duration biotech discount rate elevated

  Confidence

  medium

  Load Bearing

  false

  Basis

  Macro brief: FOMC held 3.50-3.75% on a 9-3 vote with three dissents in favour of a hike; the 2026-09-16 decision was unresolved at authoring

  If Wrong

  The capital-formation leg weakens and mass returns to base

• 06
• 11
• 07

Stopper: demand deflation. Requires declining category revenue in dollars. Falling price with rising dollars stays in base.

Oral incretin revenue beating consensus for two consecutive quarters.

Treat 2024-25 GLP-1 price assumptions as stale in both directions. Suppliers with capacity contracted against injectable volume growth should stress-test take-or-pay exposure.

analogue

• Peptide generic manufacturing meets bioequivalence and impurity requirements at volume
• At least two generic manufacturers reach commercial supply, not one
• Canadian net price is published or inferable

• Indicator

  A second major market outside Canada grants marketing authorisation for a generic semaglutide

  Source

  S-06-09

  Threshold

  second market authorisation

  Direction

  occurs

  Would Be Visible By

  2027-12

  Resolves

  One company is a project; two is a sector. A second market confirms disruption

• Indicator

  Canadian generic semaglutide reaching above 20% volume share within twelve months of launch

  Source

  S-06-09

  Threshold

  20% volume share

  Direction

  above

  Would Be Visible By

  2027-06

  Resolves

  Confirms price elasticity; below 10% keeps this in base

• Text

  Post-patent peptide supply can meet quality and impurity requirements at commercial scale

  Confidence

  low

  Load Bearing

  true

  Basis

  T-06-09 records that quality and impurity concerns have been raised and that safety surveillance for generic entrants is untested at scale

  If Wrong

  This branch stays a Canadian curiosity and its mass returns to base

• Text

  MFN reference calculations actually incorporate generic ex-US prices

  Confidence

  low

  Load Bearing

  false

  Basis

  The MFN agreements are bilateral and their reference methodology is not published

  If Wrong

  The US price effect does not materialise and only ex-US economics change

• 06
• 09
• 12

Requires a second market. A Canadian launch alone resolves to base.

Canadian generic volume share below 10% twelve months after launch.

Anyone underwriting ex-US branded incretin revenue past 2028 should price a generic scenario explicitly rather than assuming device and process patents hold.

base_rate

• A live case reaches a merits ruling, or a bill reaches floor consideration
• The four-stage position of each instrument is tracked separately: proposed, enacted, in force, enforced

• Indicator

  A Federal Register document revoking or suspending the 2026-04-02 Section 232 pharmaceutical action in its entirety

  Source

  S-06-20

  Threshold

  full revocation or suspension

  Direction

  occurs

  Would Be Visible By

  2027-12

  Resolves

  Confirms the unwind direction of regulatory

• Indicator

  Enacted legislation codifying either the MFN framework or the CNPV pilot

  Source

  S-06-20

  Threshold

  enactment, not introduction

  Direction

  occurs

  Would Be Visible By

  2028-12

  Resolves

  Confirms the codification direction

• Text

  The instruments are severable, so a ruling against one does not automatically void the others

  Confidence

  medium

  Load Bearing

  true

  Basis

  Medicare negotiation is statutory; MFN is executive; Section 232 is a proclamation - three different legal bases

  If Wrong

  A single adverse ruling collapses all three levers at once and mass moves to disruption and failure

• Text

  Section 232 actions are not exposed to the reasoning that voided the IEEPA tariffs

  Confidence

  medium

  Load Bearing

  false

  Basis

  Macro addendum: Section 232 was untouched when the Supreme Court voided IEEPA on 2026-02-20

  If Wrong

  The unwind direction becomes much more likely

• 06
• 09
• 12

Regulatory outranks base when a final instrument issues or is vacated, even if revenue and volume look base-like.

Manufacturers quietly allowing MFN agreements to lapse at renewal rather than either side litigating, which would be an unwind without a docket.

Track the four-stage position of each instrument separately and archive White House fact sheets on publication; the corpus records this content is removed at administration transitions.

analogue

• A safety communication or label action naming a class-wide effect
• Payer utilisation management tightening in response
• No offsetting new indication approvals

• Indicator

  A second boxed warning or indication withdrawal on a product approved under an accelerated pathway within twelve months

  Source

  S-06-02

  Threshold

  second occurrence

  Direction

  occurs

  Would Be Visible By

  2027-12

  Resolves

  Confirms the regulatory over-correction mechanism

• Indicator

  An FDA safety communication naming the incretin class rather than a single product

  Source

  S-06-02

  Threshold

  class-level communication

  Direction

  occurs

  Would Be Visible By

  2028-12

  Resolves

  Confirms failure; a single-product action stays in base

• Text

  A class-level safety communication would produce a sector-wide review-timeline response rather than a product-level label change

  Confidence

  low

  Load Bearing

  true

  Basis

  The Elevidys analogue produced a product-level response, not a sector-level one; extrapolating to the sector level is judgement

  If Wrong

  The branch is near-remote and mass returns to base and regulatory

• Text

  FDA's current leadership instability does not itself change the speed of a safety response

  Confidence

  low

  Load Bearing

  false

  Basis

  Six CDER and six CBER leaders since January 2025 against rising approval counts

  If Wrong

  The response could be either faster and blunter or slower and narrower

• 06
• 11
• 07

Failure outranks all other branches on occurrence. The distinguishing observable is a class-level FDA communication, not a product-level one.

Ten-year real-world exposure data published in a Tier A journal showing no class-level signal.

Nothing in this branch is a reason to change clinical practice; it is a reason for suppliers and investors concentrated in one mechanism of action to hold diversification they would not otherwise hold.